Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV Infections

In brief

Despite treatment with anti-HIV drugs, people infected with HIV continue to have problems with their immune systems. This study will evaluate whether the drug thalidomide, which stimulates the immune system's T cells, can improve immune system function in people with HIV.

Key facts

Study ID

NCT00053430

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

40

Starts

2001-04-01

Expected to finish

2006-02-01

Last updated by the study team

2009-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• HIV-infected for at least 5 years prior to study entry
• CD4 count of 300/mm3 or above
• Pre-HAART nadir CD4 count of 300/mm3 or less
• CMV infection
• HAART for 12 months prior to study entry
• Same effective HAART regimen for 3 months prior to study entry
• HIV viral load less than 200 copies/ml
• Clinically stable

You may not qualify if…

• Active opportunistic infection
• Females of childbearing potential

Where it is running

• University of Miami School of Medicine — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.